NasdaqGS:FTRELife Sciences
Will Fortrea (FTRE) Executive Shifts Refocus Its Clinical Margin Story Or Signal Strategic Drift?
On 17 February 2026, Fortrea Holdings expanded its executive team by dedicating Oren Cohen, MD solely to the chief medical officer role and appointing Scott Dove, PhD as president of Clinical Pharmacology Services, with both serving on the Executive Committee.
This leadership reshaping concentrates seasoned medical and early development expertise at the top of the organization, potentially affecting how Fortrea runs trials and manages its clinical pharmacology operations.
Next, we’ll examine...